KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Free Cash Flow (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Free Cash Flow for 11 consecutive years, with -$93.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 91.75% to -$93.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$345.9 million through Dec 2025, down 142.03% year-over-year, with the annual reading at -$345.9 million for FY2025, 142.03% down from the prior year.
  • Free Cash Flow hit -$93.1 million in Q4 2025 for CRISPR Therapeutics AG, down from -$84.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $808.3 million in Q2 2021 to a low of -$151.6 million in Q2 2022.
  • Historically, Free Cash Flow has averaged -$37.6 million across 5 years, with a median of -$90.6 million in 2023.
  • Biggest five-year swings in Free Cash Flow: soared 2899.56% in 2021 and later tumbled 565.92% in 2022.
  • Year by year, Free Cash Flow stood at -$21.9 million in 2021, then crashed by 565.92% to -$145.6 million in 2022, then skyrocketed by 39.51% to -$88.1 million in 2023, then skyrocketed by 44.88% to -$48.5 million in 2024, then plummeted by 91.75% to -$93.1 million in 2025.
  • Business Quant data shows Free Cash Flow for CRSP at -$93.1 million in Q4 2025, -$84.7 million in Q3 2025, and -$114.0 million in Q2 2025.